Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | CASP1 | P29466 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26797325 | 0.87 | MGLL (0.53) | MGLLALDH1A1L3MBTL1NPSR1KMT2A | |
| SCHEMBL2721497 | 0.85 | POLB (0.36) | ALDH1A1PKMSMN1; SMN2MEN1KMT2A | |
| SCHEMBL4400113 | 0.82 | ALDH1A1 (0.58) | ALDH1A1PKMPTGS1PTGS2NPSR1 | |
| SCHEMBL15415134 | 0.82 | MGLL (0.42) | MGLLALDH1A1PKMPTGS1PTGS2 | |
| SCHEMBL24939802 | 0.81 | TSHR (0.42) | ALDH1A1PKML3MBTL1SMN1; SMN2MEN1 | |
| SCHEMBL16283417 | 0.81 | RGS4 (0.43) | MGLLALDH1A1PKMPTGS1PTGS2 | |
| SCHEMBL8888852 | 0.80 | PTGS1 (0.50) | ALDH1A1PKMPTGS1PTGS2SMN1; SMN2 | |
| SCHEMBL15075446 | 0.79 | KMT2A (0.48) | ALDH1A1NPSR1MEN1KMT2A | |
| SCHEMBL15215618 | 0.78 | MGLL (0.71) | MGLLALDH1A1PKMPTGS1PTGS2 | |
| SCHEMBL8885866 | 0.78 | MGLL (0.41) | MGLLALDH1A1PKMPTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2793928-B1 | PROCESS FOR PURIFYING A SAMPLE OF H38C2 ANTIBODY | PFIZER (US) | 2017-03-15 | — | — | EP | disclosed |
| EP-2793928-B1 | PROCESS FOR PURIFYING A SAMPLE OF H38C2 ANTIBODY | PFIZER (US) | 2017-03-15 | — | — | EP | disclosed |
| US-9163227-B2 | Anti-diabetic compounds | COVX TECHNOLOGIES IRELAND LIMITED (IE) | 2015-10-20 | — | — | US | disclosed |
| US-9163227-B2 | Anti-diabetic compounds | COVX TECHNOLOGIES IRELAND LIMITED (IE) | 2015-10-20 | — | — | US | disclosed |
| US-9163227-B2 | Anti-diabetic compounds | COVX TECHNOLOGIES IRELAND LIMITED (IE) | 2015-10-20 | — | — | US | disclosed |
| EP-2793928-A2 | ANTI-DIABETIC COMPOUNDS | Pfizer Inc (US) | 2014-10-29 | — | — | EP | disclosed |
| US-8722622-B2 | FGF21 conjugates and anti-diabetic uses thereof | COVX TECHNOLOGIES IRELAND, LIMITED (IE) | 2014-05-13 | — | — | US | disclosed |
| US-8722622-B2 | FGF21 conjugates and anti-diabetic uses thereof | COVX TECHNOLOGIES IRELAND, LIMITED (IE) | 2014-05-13 | — | — | US | disclosed |
| US-8722622-B2 | FGF21 conjugates and anti-diabetic uses thereof | COVX TECHNOLOGIES IRELAND, LIMITED (IE) | 2014-05-13 | — | — | US | disclosed |
| EP-2635309-A2 | ANTI-DIABETIC COMPOUNDS | CovX Technologies Ireland Limited (IE) | 2013-09-11 | — | — | EP | disclosed |
| WO-2013093720-A2 | ANTI-DIABETIC COMPOUNDS | PFIZER INC. (US) | 2013-06-27 | — | — | WO | disclosed |
| WO-2013093720-A2 | ANTI-DIABETIC COMPOUNDS | PFIZER INC. (US) | 2013-06-27 | — | — | WO | disclosed |
| US-20130164310-A1 | ANTI-DIABETIC COMPOUNDS | COVX TECHNOLOGIES IRELAND LIMITED | 2013-06-27 | — | — | US | disclosed |
| US-20130164310-A1 | ANTI-DIABETIC COMPOUNDS | COVX TECHNOLOGIES IRELAND LIMITED | 2013-06-27 | — | — | US | disclosed |
| US-20130164310-A1 | ANTI-DIABETIC COMPOUNDS | COVX TECHNOLOGIES IRELAND LIMITED | 2013-06-27 | — | — | US | disclosed |
| US-20120282279-A1 | Anti-Diabetic Compounds | COVX TECHNOLOGIES IRELAND LIMITED (IE) | 2012-11-08 | — | — | US | disclosed |
| US-20120282279-A1 | Anti-Diabetic Compounds | COVX TECHNOLOGIES IRELAND LIMITED (IE) | 2012-11-08 | — | — | US | disclosed |
| US-20120282279-A1 | Anti-Diabetic Compounds | COVX TECHNOLOGIES IRELAND LIMITED (IE) | 2012-11-08 | — | — | US | disclosed |
| WO-2012059873-A2 | ANTI-DIABETIC COMPOUNDS | COVX TECHNOLOGIES IRELAND, LTD. (IE) | 2012-05-10 | — | — | WO | disclosed |
| WO-2012059873-A2 | ANTI-DIABETIC COMPOUNDS | COVX TECHNOLOGIES IRELAND, LTD. (IE) | 2012-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120282279-A1 | Anti-Diabetic Compounds | GLP1R, FGF2, FGFR1 | MGLL 1667/4885ALDH1A1 1416/4885PKM 4214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.